Open an account

Novocure

NVCR · NASDAQ

$14.68−$0.42 (−2.78%)TodayMarket closed ·
Prev close $15.10

About NVCR

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The firm's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.

Employees
1,605
Headquarters
Saint Helier
Listed
Oct 1, 2015
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
novocure.com

NVCR key statistics

Market cap
1.71B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.61M
Volume
1.13M
Open price
$14.85
High today
$14.97
Low today
$14.53
52 Week high
$21.45
52 Week low
$9.82

Novocure (NVCR) at a glance

Novocure (NVCR) last traded at $14.68, with a market cap of 1.71B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $14.53 and $14.97. The current price is 1.0% above the day's low and 1.9% below its high.

Volume so far is 1.13M shares, below the average of 1.61M shares a day.

Over the past year Novocure has ranged from $9.82 to $21.45, and now sits 42% of the way up that range.

Novocure met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.17 per share against an estimate of -$0.3381.

The average analyst price target is $29.41, 100.3% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

40%of 5 analyst ratings say Buy
  • Buy40.0%
  • Hold60.0%
  • Sell0.0%
Price target · 9 analystsAvg $29.41
Low
$20.20
Now
$14.68
High
$54.60

NVCR earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 30.1% on average.

  1. Q3 FY24: reported -$0.28 per share against an estimate of -$0.3405
  2. Q4 FY24: reported -$0.61 per share against an estimate of -$0.3507
  3. Q1 FY25: reported -$0.31 per share against an estimate of -$0.4736
  4. Q2 FY25: reported -$0.36 per share against an estimate of -$0.3918
  5. Q3 FY25: reported -$0.33 per share against an estimate of -$0.4294
  6. Q4 FY25: reported -$0.22 per share against an estimate of -$0.4197
  7. Q1 FY26: reported -$0.62 per share against an estimate of -$0.5231
  8. Q2 FY26: reported -$0.17 per share against an estimate of -$0.3381

NVCR news

  • Press releaseBusiness Wire

    Novocure’s Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer

  • Press releaseBusiness Wire

    Novocure to Report Third Quarter 2026 Financial Results

  • Press releaseBusiness Wire

    Novocure Announces Upcoming Investor Events

  • Akanksha Bakshi

    NovoCure's Strongest Quarter Ever Isn't Enough to Stop NVCR Stock From Sliding

  • Avi Kapoor

    Crude Oil Rises Sharply; T-Mobile Shares Fall Following Q2 Results

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • Press releaseBusiness Wire

    Novocure Reports Second Quarter 2026 Financial Results

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.